Eli Lilly unveiled a $3.5 billion manufacturing facility in Lehigh Valley, Pennsylvania, dedicated to its next‑generation obesity injectables, including retatrutide. The plant will produce drug substance and combination device components for current and future weight‑loss biologics and is designed to scale for projected demand. Lilly said the site will support multiple molecules and devices, reflecting vertical integration to secure supply for its obesity franchise. The company expects the facility to increase capacity for injectable peptides and delivery systems, aiming to meet rising global demand as competitive GLP‑1 and multi‑agonist therapies reach the market. For investors and supply‑chain managers, the investment signals pharma confidence in durable demand for obesity therapeutics and a strategic shift to in‑house manufacturing to avoid bottlenecks in drug and device output.